A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT00786201 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Fibrosis

Interventions

DRUG: Placebo
DRUG: CNTO 888 1 mg/kg
DRUG: CNTO 888 5 mg/kg
DRUG: CNTO 888 15 mg/kg

Sponsor

Centocor, Inc.